Control group:ADT

3 trials

Sponsors

Chinese PLA General Hospital, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Shanghai University of Traditional Chinese Medicine

Conditions

PROSTATE CANCERhigh risk localized prostate cancer with homologous recombination repair abnormalities

Early Phase 1

Study on the mechanism of castration and metabolic syndrome in prostate cancer treated by ''Hua-Tan Tong-Luo'' approach

RecruitingChiCTR2000036966

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Shanghai University of Traditional Chinese MedicinePROSTATE CANCER

Start: 2020-10-01Updated: 2020-09-28

Study on the mechanism of castration and metabolic syndrome in prostate cancer treated by ''Hua-Tan Tong-Luo'' approach

RecruitingITMCTR2000003718

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Shanghai University of Traditional Chinese MedicinePROSTATE CANCER

Start: 2020-10-01Updated: 2023-02-20

Phase 2

A prospective, randomized, single center, phase II study of Fluzoparib combined with ADT for high risk localized prostate cancer with homologous recombination repair abnormalities before prostatectomy

RecruitingChiCTR2000035193

Chinese PLA General Hospitalhigh risk localized prostate cancer with homologous recombination repair abnormalities

Start: 2020-08-03Updated: 2020-08-03